Camrelizumab
One of China's most widely used PD-1 blockers, approved there for oesophageal, liver, lung, and other cancers; not approved in the US.
Humanised IgG4 anti-PD-1 (Jiangsu Hengrui). ESCORT (second-line ESCC) and ESCORT-1st (first-line with chemotherapy, OS 15.3 vs 12.0 months) in China; ESCORT-NEO neoadjuvant; CARES-310 with rivoceranib in HCC (OS 22.1 vs 15.2 months). A US BLA for the HCC combination received complete response letters (2024, 2025) over manufacturing and travel-inspection issues. Distinctive toxicity: reactive cutaneous capillary endothelial proliferation (RCCEP) in most patients.
1.Camrelizumab binds PD-1 on T cells
- Route
- Intravenous
- Schedule
- 200 mg every 2-3 weeks
- Medicare
- Not covered (not FDA-approved)
Not FDA-approved, so there is no US coverage; access is only through a clinical trial or an FDA expanded-access request.
- Commercial insurance
- unknown
Not FDA-approved, so there is no US coverage; access is only through a clinical trial or an FDA expanded-access request.
Sources: CMS Medicare Coverage Database (NCDs and LCDs). Not medical or financial advice; verify with your plan.
- Notes
- No UK marketing authorisation as of September 2026, so no NICE appraisal. Access only through a clinical trial or a company early access scheme.
- NHS England
- Not routinely funded
Sources: NICE search: camrelizumab. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.
Compare all products across the US, EU, UK, Japan, China and Australia →
- May 2024Complete response letterUS
Complete response letter for camrelizumab + rivoceranib in HCC (manufacturing/inspection)
- Mar 2025Complete response letterUS
Second complete response letter
Approvals
| Region | Year | Indication |
|---|---|---|
| China | 2019 | Classical Hodgkin lymphoma; subsequently HCC, NSCLC, ESCC (second line 2020, first line with chemotherapy 2021), nasopharyngeal |
| Adverse event |
|---|
| Reactive cutaneous capillary endothelial proliferation (RCCEP) |
| Immune-related adverse events |
Very common; benign, resolves after stopping. Events listed without rates were not read from a primary source; see the label. Blank cells mean the figure was not sourced, not that it is zero.
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials in OnCo
Latest papers
topQuery for this drug: (TITLE:"Camrelizumab" OR ABSTRACT:"Camrelizumab" OR TITLE:"AiRuiKa" OR ABSTRACT:"AiRuiKa" OR TITLE:"SHR-1210" OR ABSTRACT:"SHR-1210") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Camrelizumab, not a curated reading list.